Exposures to perfluoroalkyl substances and asthma phenotypes in childhood

Exposures to perfluoroalkyl substances and asthma phenotypes in childhood: an investigation of the COPSAC2010 cohort

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

Fulltext
Forlagets udgivne version, 375 KB, PDF-dokument

Astrid Sevelsted
Casper Emil Tingskov Pedersen
Gözde Gürdeniz
Rasmussen, Morten Arendt
Jörg Schullehner
Kalliroi Sdougkou
Jonathan W. Martin
Jessica Lasky-Su
Andreanne Morin
Carole Ober
Schoos, Ann-Marie Malby
Jakob Stokholm
Bønnelykke, Klaus
Chawes, Bo Lund Krogsgaard
Hans Bisgaard

Background
Exposure to perfluoroalkyl substances may affect offspring immune development and thereby increase risk of childhood asthma, but the underlying mechanisms and asthma phenotype affected by such exposure is unknown.

Methods
In the Danish COPSAC2010 cohort of 738 unselected pregnant women and their children plasma PFOS and PFOA concentrations were semi-quantified by untargeted metabolomics analyses and calibrated using a targeted pipeline in mothers (gestation week 24 and 1 week postpartum) and children (age ½, 1½ and 6 years). We examined associations between pregnancy and childhood PFOS and PFOA exposure and childhood infections, asthma, allergic sensitization, atopic dermatitis, and lung function measures, and studied potential mechanisms by integrating data on systemic low-grade inflammation (hs-CRP), functional immune responses, and epigenetics.

Findings
Higher maternal PFOS and PFOA exposure during pregnancy showed association with a non-atopic asthma phenotype by age 6, a protection against sensitization, and no association with atopic asthma or lung function, or atopic dermatitis. The effect was primarily driven by prenatal exposure. There was no association with infection proneness, low-grade inflammation, altered immune responses or epigenetic changes.

Interpretations
Prenatal exposure to PFOS and PFOA, but not childhood exposure, specifically increased the risk of low prevalent non-atopic asthma, whereas there was no effect on atopic asthma, lung function, or atopic dermatitis.

Funding
All funding received by COPSAC are listed on www.copsac.com. The Lundbeck Foundation (Grant no R16-A1694); The Novo Nordic Foundation (Grant nos NNF20OC0061029, NNF170C0025014, NNF180C0031764); The Ministry of Health (Grant no 903516); Danish Council for Strategic Research (Grant no 0603-00280B); and The Capital Region Research Foundation have provided core support to the COPSAC research center. COPSAC acknowledges the National Facility for Exposomics (SciLifeLab, Sweden) for supporting calibration of the untargeted metabolomics PFAS data. BC and AS has received funding for this project from the European Union’s Horizon 2020 research and innovation programme (BC: grant agreement No. 946228 DEFEND; AS: grant agreement No. 864764 HEDIMED).

Originalsprog	Engelsk
Artikelnummer	104699
Tidsskrift	EBioMedicine
Vol/bind	94
Antal sider	12
ISSN	2352-3964
DOI	https://doi.org/10.1016/j.ebiom.2023.104699
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
We express our deepest gratitude to the children and families of the COPSAC2010 cohort for all their support and commitment. We acknowledge and appreciate the unique efforts of the COPSAC research team. COPSAC acknowledges the National Facility for Exposomics (SciLifeLab, Sweden) for supporting calibration of the untargeted metabolomics PFAS data. We acknowledge all funding received by COPSAC, listed on www.copsac.com . The Lundbeck Foundation (Grant no R16-A1694 ); The Ministry of Health , Denmark (Grant no 903516 ); Danish Council for Strategic Research (Grant no 0603-00280B ) and The Capital Region Research Foundation have provided core support to the COPSAC research centre. Funding for this project from the European Union’s Horizon 2020 research and innovation programme (BC: grant agreement No. 946228 ; AS: grant agreement No 864764 HEDIMED).

Funding Information:
All funding received by COPSAC are listed on www.copsac.com. The Lundbeck Foundation (Grant no R16-A1694); The Novo Nordic Foundation (Grant nos NNF20OC0061029, NNF170C0025014, NNF180C0031764); The Ministry of Health (Grant no 903516); Danish Council for Strategic Research (Grant no 0603-00280B); and The Capital Region Research Foundation have provided core support to the COPSAC research center. COPSAC acknowledges the National Facility for Exposomics (SciLifeLab, Sweden) for supporting calibration of the untargeted metabolomics PFAS data. BC and AS has received funding for this project from the European Union's Horizon 2020 research and innovation programme (BC: grant agreement No. 946228 DEFEND; AS: grant agreement No. 864764 HEDIMED).We express our deepest gratitude to the children and families of the COPSAC2010 cohort for all their support and commitment. We acknowledge and appreciate the unique efforts of the COPSAC research team. COPSAC acknowledges the National Facility for Exposomics (SciLifeLab, Sweden) for supporting calibration of the untargeted metabolomics PFAS data. We acknowledge all funding received by COPSAC, listed on www.copsac.com. The Lundbeck Foundation (Grant no R16-A1694); The Ministry of Health, Denmark (Grant no 903516); Danish Council for Strategic Research (Grant no 0603-00280B) and The Capital Region Research Foundation have provided core support to the COPSAC research centre. Funding for this project from the European Union's Horizon 2020 research and innovation programme (BC: grant agreement No. 946228; AS: grant agreement No 864764 HEDIMED).

Publisher Copyright:
© 2023 The Author(s)

ID: 365877803